Price
No data yet.
Social Signal Score
Revenue
$57.44M+58.98%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vivek K. Jayaraman
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 268
- Beta
- 1.77
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -3.22
Financials
Revenue
$57.44M+59.0%Net Income
$-2.94MEBITDA
$-712.0KFree Cash Flow
$-3.53MEPS (diluted)
$-0.01Shares Outstanding (diluted)
200.56M+16.7%Operating Expenses
$37.25MCash & Debt
$56.26MRevenue by Segment (annual)
$233.80MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $206.13M | $-15.63M | $-0.08 |
| 2024 | $180.27M | $-20.92M | $-0.11 |
| 2023 | $156.37M | $-37.49M | $-0.21 |
| 2022 | $162.05M | $-42.78M | $-0.24 |
| 2021 | $130.86M | $-54.37M | $-0.32 |
| 2020 | $91.92M | $-59.86M | $-0.37 |
| 2019 | $74.65M | $-71.24M | $-0.51 |
| 2018 | $60.91M | $-57.56M | $-0.44 |
| 2017 | $43.57M | $-60.59M | $-0.56 |
| 2016 | $37.18M | $-62.91M | $-0.62 |
| 2015 | $34.22M | $-55.87M | $-0.58 |
| 2014 | $36.50M | $-38.57M | $-0.52 |
| 2013 | $39.66M | $-43.34M | $-0.64 |
| 2012 | $36.70M | $-15.92M | $-0.29 |
Valuation
CERShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsseekingalpha.com·1d ago·Neutral
Cerus: This Blood-Safety Underdog Should Be Earning More Respect Cerus (CERS) is pivoting toward higher-value therapeutic products while reducing its research cost burden, aided by substantial government funding. Q2 2026 results signal an inflection point: product revenue grew 10%, operating expenses fell 7%, and adjusted EBITDA more than tripled year-over-year. Management raised full-year revenue guidance for the second time this year, now projecting $229–231 million, reflecting growing confide…
View source ↗
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $-0.01 per share
Typical surprise +20.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$-0.01 vs $-0.01beat
- Thu, Apr 30$-0.01 vs $-0.03beat
- Mon, Mar 2$-0.01 vs $-0.01beat
- Thu, Nov 6$-0.00 vs $-0.02beat
- Tue, Aug 5$-0.03 vs $-0.02miss
- Thu, May 1$-0.04 vs $-0.05beat
Estimates and results for CERS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CERS officers and directors.
- Bought
- $31k
- Sold
- $4.6m
1 trade
47 trades
- Jensen Chrystalsold
- Jayaraman Vivek Ksold
- Green Kevin Dennissold
- Jayaraman Vivek Ksold
- Jensen Chrystalsold
- Greenman William Marinersold
- Bjerkholt Ericsold
- Jayaraman Vivek Ksold
52 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.